221 related articles for article (PubMed ID: 18163485)
1. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
Tak PP; Thurlings RM; Rossier C; Nestorov I; Dimic A; Mircetic V; Rischmueller M; Nasonov E; Shmidt E; Emery P; Munafo A
Arthritis Rheum; 2008 Jan; 58(1):61-72. PubMed ID: 18163485
[TBL] [Abstract][Full Text] [Related]
2. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
Dall'Era M; Chakravarty E; Wallace D; Genovese M; Weisman M; Kavanaugh A; Kalunian K; Dhar P; Vincent E; Pena-Rossi C; Wofsy D
Arthritis Rheum; 2007 Dec; 56(12):4142-50. PubMed ID: 18050206
[TBL] [Abstract][Full Text] [Related]
3. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
Genovese MC; Kinnman N; de La Bourdonnaye G; Pena Rossi C; Tak PP
Arthritis Rheum; 2011 Jul; 63(7):1793-803. PubMed ID: 21452293
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.
Nestorov I; Munafo A; Papasouliotis O; Visich J
J Clin Pharmacol; 2008 Apr; 48(4):406-17. PubMed ID: 18303125
[TBL] [Abstract][Full Text] [Related]
5. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
van Vollenhoven RF; Kinnman N; Vincent E; Wax S; Bathon J
Arthritis Rheum; 2011 Jul; 63(7):1782-92. PubMed ID: 21452294
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
7. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
8. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.
Pena-Rossi C; Nasonov E; Stanislav M; Yakusevich V; Ershova O; Lomareva N; Saunders H; Hill J; Nestorov I
Lupus; 2009 May; 18(6):547-55. PubMed ID: 19395457
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
van Vollenhoven RF; Wax S; Li Y; Tak PP
Arthritis Rheumatol; 2015 Nov; 67(11):2828-36. PubMed ID: 26137975
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis.
Chen X; Zhao Q; Hou Y; Jiang J; Zhong W; Wang W; Yao X; Li L; Fang J; Zhang F; Hu P
Br J Clin Pharmacol; 2016 Jul; 82(1):41-52. PubMed ID: 26917504
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.
Chen X; Hou Y; Jiang J; Zhao Q; Zhong W; Wang W; Yao X; Li L; Fang J; Zhang F; Hu P
Clin Pharmacokinet; 2014 Nov; 53(11):1033-44. PubMed ID: 25179916
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
Munafo A; Priestley A; Nestorov I; Visich J; Rogge M
Eur J Clin Pharmacol; 2007 Jul; 63(7):647-56. PubMed ID: 17473917
[TBL] [Abstract][Full Text] [Related]
13. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.
Bracewell C; Isaacs JD; Emery P; Ng WF
Expert Opin Biol Ther; 2009 Jul; 9(7):909-19. PubMed ID: 19522556
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus.
Nestorov I; Papasouliotis O; Pena Rossi C; Munafo A
J Pharm Sci; 2010 Jan; 99(1):524-38. PubMed ID: 19743503
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma.
Ansell SM; Witzig TE; Inwards DJ; Porrata LF; Ythier A; Ferrande L; Nestorov I; Devries T; Dillon SR; Hausman D; Novak AJ
Clin Cancer Res; 2008 Feb; 14(4):1105-10. PubMed ID: 18281543
[TBL] [Abstract][Full Text] [Related]
16. Atacicept as an investigated therapy for rheumatoid arthritis.
Richez C; Truchetet ME; Schaeverbeke T; Bannwarth B
Expert Opin Investig Drugs; 2014 Sep; 23(9):1285-94. PubMed ID: 25078871
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
[TBL] [Abstract][Full Text] [Related]
19. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
Huizinga TW; Batalov A; Stoilov R; Lloyd E; Wagner T; Saurigny D; Souberbielle B; Esfandiari E
Arthritis Res Ther; 2017 Mar; 19(1):53. PubMed ID: 28274253
[TBL] [Abstract][Full Text] [Related]
20. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
